Upgrading Our Growth Forecast for Becton, Dickinson
Across the firm, we are seeing the effects of significant R&D investments, with BD's pipeline the strongest it's been in our history of covering this narrow-moat medical technology company.
We're raising our fair value estimate for Becton, Dickinson and Co (BDX) to $186 per share, mainly due to our upgraded long-term growth forecast across most business lines. While some changes are minuscule (50-100 basis points), they have a significant impact on a company that recently saw growth in a 3%-4% range. Across the firm, we are seeing the effects of significant R&D investments, with BD's pipeline the strongest it's been in our history of covering the firm. The entire portfolio is expanding, including BD's presence in informatics, which historically hasn't been its core focus. Device interconnectivity is an important pillar of BD's focus on the entire care continuum, particularly in areas like diabetes, where BD has always been strong, and is an attractive opportunity, both in the developed world and in emerging markets.
The essential nature of BD's medical products has given the firm ample cash flows for reinvestment in areas such as diabetes, injectables, and biosciences. The company has also built out massive presence in emerging markets, with its distribution and manufacturing network unparalleled in the med tech world. The acquisition of CareFusion was a culmination of the firm’s transformative efforts over the past few years, and the ultimate payoff of this transaction--profitable growth--is becoming evident. CareFusion's product suite provided many complementary opportunities to BD’s own products, which should yield revenue synergies worldwide, particularly in emerging markets, where CareFusion’s presence has historically been lacklustre.
CareFusion also gives BD an opportunity to apply its penchant for running efficient operations to squeeze CareFusion’s bloated infrastructure. Cost synergies here aren’t just management-speak but are instead real, given CareFusion’s inefficient infrastructure. We estimate BD to exceed its conservative synergy guidance; coupled with incremental revenue opportunities, this should ultimately result in value accretion.
Morningstar Premium Members gain exclusive access to our full analyst reports, including fair value estimates, bull and bear breakdowns, and risk analyses. Not a Premium Member? Get this and other reports immediately when you try Morningstar Premium free for 14 days.
Alex Morozov does not own (actual or beneficial) shares in any of the securities mentioned above. Find out about Morningstar’s editorial policies.
Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data.
We’d like to share more about how we work and what drives our day-to-day business.
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions. Our investment management business generates asset-based fees, which are calculated as a percentage of assets under management. We also sell both admissions and sponsorship packages for our investment conferences and advertising on our websites and newsletters.
How we use your information depends on the product and service that you use and your relationship with us. We may use it to:
To learn more about how we handle and protect your data, visit our privacy center.
Maintaining independence and editorial freedom is essential to our mission of empowering investor success. We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished thinking of our people and exacting analysis of our research processes. Our authors can publish views that we may or may not agree with, but they show their work, distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive.
To further protect the integrity of our editorial content, we keep a strict separation between our sales teams and authors to remove any pressure or influence on our analyses and research.
Read our editorial policy to learn more about our process.